Cargando…

(18)F-THK5351 Positron Emission Tomography Imaging in Neurodegenerative Tauopathies

Introduction: We aimed to determine whether in vivo tau deposits and monoamine oxidase B (MAO-B) detection using (18)F-THK5351 positron emission tomography (PET) can assist in the differential distribution in patients with corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), and Alzhei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ezura, Michinori, Kikuchi, Akio, Okamura, Nobuyuki, Ishiki, Aiko, Hasegawa, Takafumi, Harada, Ryuichi, Watanuki, Shoichi, Funaki, Yoshihito, Hiraoka, Kotaro, Baba, Toru, Sugeno, Naoto, Yoshida, Shun, Kobayashi, Junpei, Kobayashi, Michiko, Tano, Ohito, Ishiyama, Shun, Nakamura, Takaaki, Nakashima, Ichiro, Mugikura, Shunji, Iwata, Ren, Taki, Yasuyuki, Furukawa, Katsutoshi, Arai, Hiroyuki, Furumoto, Shozo, Tashiro, Manabu, Yanai, Kazuhiko, Kudo, Yukitsuka, Takeda, Atsushi, Aoki, Masashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668184/ https://www.ncbi.nlm.nih.gov/pubmed/34912209 http://dx.doi.org/10.3389/fnagi.2021.761010

Ejemplares similares

Neuroimaging-pathological correlations of [(18)F]THK5351 PET in progressive supranuclear palsy
por: Ishiki, Aiko, et al.
Publicado: (2018)

Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351
por: Lockhart, Samuel N., et al.
Publicado: (2016)

Longitudinal Assessment of Tau Pathology in Patients with Alzheimer’s Disease Using [(18)F]THK-5117 Positron Emission Tomography
por: Ishiki, Aiko, et al.
Publicado: (2015)

Assessing THK523 selectivity for tau deposits in Alzheimer’s disease and non–Alzheimer’s disease tauopathies
por: Fodero-Tavoletti, Michelle T, et al.
Publicado: (2014)

[(18)F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy
por: Brendel, Matthias, et al.
Publicado: (2018)

[(18)F]THK-5351 PET imaging in early-stage semantic variant primary progressive aphasia: a report of two cases and a literature review
por: Kobayashi, Ryota, et al.
Publicado: (2018)

(18)F-THK5351 PET Imaging in the Behavioral Variant of Frontotemporal Dementia
por: Nam, Gijin, et al.
Publicado: (2018)

[(18)F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment
por: Jeong, Hye Jin, et al.
Publicado: (2020)

Error propagation analysis of seven partial volume correction algorithms for [(18)F]THK-5351 brain PET imaging
por: Oyama, Senri, et al.
Publicado: (2020)

Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains
por: Lemoine, Laetitia, et al.
Publicado: (2017)

Distinct [(18)F]THK5351 binding patterns in primary progressive aphasia variants
por: Schaeverbeke, Jolien, et al.
Publicado: (2018)

Regional cerebral THK5351 accumulations correlate with neuropsychological test scores in Alzheimer continuum
por: Im, SungWoon, et al.
Publicado: (2023)

Visualization of ischemic stroke-related changes on (18)F-THK-5351 positron emission tomography
por: Huang, Kuo-Lun, et al.
Publicado: (2018)

(18)F-THK5351 PET Imaging in Nonfluent-Agrammatic Variant Primary Progressive Aphasia
por: Yoon, Cindy W, et al.
Publicado: (2018)

Relationships between [(18)F]-THK5351 Retention and Language Functions in Primary Progressive Aphasia
por: Jeong, Hye Jin, et al.
Publicado: (2019)

Early brainstem ([18F])THK5351 uptake is linked to cortical hyperexcitability in healthy aging
por: Van Egroo, Maxime, et al.
Publicado: (2021)

High sensitivity of asymmetric (18)F-THK5351 PET abnormality in patients with corticobasal syndrome
por: Kurihara, Masanori, et al.
Publicado: (2023)

Evaluation of the biodistribution and radiation dosimetry of the (18)F-labelled amyloid imaging probe [(18)F]FACT in humans
por: Shidahara, Miho, et al.
Publicado: (2013)

Perfusion-Phase [(18)F]THK5351 Tau-PET Imaging as a Surrogate Marker for Neurodegeneration
por: Brendel, Matthias, et al.
Publicado: (2017)

Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain
por: Ng, Kok Pin, et al.
Publicado: (2017)

[(18)F]THK-5351 PET Patterns in Patients With Alzheimer’s Disease and Negative Amyloid PET Findings
por: Oh, Minyoung, et al.
Publicado: (2022)

THK5351 and flortaucipir PET with pathological correlation in a Creutzfeldt-Jakob disease patient: a case report
por: Kim, Hee Jin, et al.
Publicado: (2019)

(18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2020)

Combination of automated brain volumetry on MRI and quantitative tau deposition on THK-5351 PET to support diagnosis of Alzheimer’s disease
por: Kim, Minjae, et al.
Publicado: (2021)

Involvement of the Precuneus/Posterior Cingulate Cortex Is Significant for the Development of Alzheimer’s Disease: A PET (THK5351, PiB) and Resting fMRI Study
por: Yokoi, Takamasa, et al.
Publicado: (2018)

Voxel-based correlation of (18)F-THK5351 accumulation and gray matter volume in the brain of cognitively normal older adults
por: Shigemoto, Yoko, et al.
Publicado: (2019)

Rasagiline, a monoamine oxidase B inhibitor, reduces in vivo [(18)F]THK5351 uptake in progressive supranuclear palsy
por: Ng, Kok Pin, et al.
Publicado: (2019)

(18)F–THK–5351, Fluorodeoxyglucose, and Florbetaben PET Images in Atypical Alzheimer’s Disease: A Pictorial Insight into Disease Pathophysiology
por: Park, Sohee, et al.
Publicado: (2021)

Voxel-based correlation of (18)F-THK5351 accumulation with gray matter structural networks in cognitively normal older adults
por: Shigemoto, Yoko, et al.
Publicado: (2021)

Longitudinal Assessment of Tau-Associated Pathology by (18)F-THK5351 PET Imaging: A Histological, Biochemical, and Behavioral Study
por: Moreno-Gonzalez, Ines, et al.
Publicado: (2021)

Tau PET With (18)F-THK-5351 Taiwan Patients With Familial Alzheimer's Disease With the APP p.D678H Mutation
por: Huang, Chin-Chang, et al.
Publicado: (2019)

Author Correction: (18)F-THK5351 PET imaging in patients with progressive supranuclear palsy: associations with core domains and diagnostic certainty
por: Hsu, Jung-Lung, et al.
Publicado: (2021)

Gray matter structural networks related to (18)F-THK5351 retention in cognitively normal older adults and Alzheimer's disease patients
por: Shigemoto, Yoko, et al.
Publicado: (2021)

(18)F-THK5351 PET Positivity and Longitudinal Changes in Cognitive Function in β-Amyloid-Negative Amnestic Mild Cognitive Impairment
por: Chun, Min Young, et al.
Publicado: (2022)

(11)C-Pittsburgh compound B and (18)F-THK 5351 positron emission tomography brain imaging in cognitively normal individuals
por: Chotipanich, Chanisa, et al.
Publicado: (2020)

(18)F-THK5351 PET for visualizing predominant lesions of pathologically confirmed corticobasal degeneration presenting with frontal behavioral-spatial syndrome
por: Saitoh, Yuji, et al.
Publicado: (2022)

Imaging of Reactive Astrogliosis by Positron Emission Tomography
por: Harada, Ryuichi, et al.
Publicado: (2022)

Dual tracer tau PET imaging reveals different molecular targets for (11)C-THK5351 and (11)C-PBB3 in the Alzheimer brain
por: Chiotis, Konstantinos, et al.
Publicado: (2018)

Temporal and spatial changes in reactive astrogliosis examined by (18)F-THK5351 positron emission tomography in a patient with severe traumatic brain injury
por: Hatakeyama, Tetsuhiro, et al.
Publicado: (2021)

Characteristics of Tau and Its Ligands in PET Imaging
por: Harada, Ryuichi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5gnj2bjorln2ngco21kh0eqq7o